Latest News | Lupin Gets Tentative Nod from USFDA to Market Generic Brexpiprazole Tablets
Get latest articles and stories on Latest News at LatestLY. Drug firm Lupin on Wednesday said it has received tentative nod from the US health regulator to market generic Brexpiprazole tablets, which are used with anti-depressant medicines for the treatment of major depressive disorder, in the American market.
New Delhi, Oct 6 (PTI) Drug firm Lupin on Wednesday said it has received tentative nod from the US health regulator to market generic Brexpiprazole tablets, which are used with anti-depressant medicines for the treatment of major depressive disorder, in the American market.
The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market generic Brexpiprazole tablets in the strengths of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, Lupin said in a regulatory filing.
The product is a generic version of Otsuka Pharmaceutical Co Ltd's Rexulti tablets in the same strengths, it added.
These tablets will be manufactured at the company's Plthampur facility, Lupin said.
Also Read | Indian Users Reportedly Conned by Fake E-Commerce Websites Amid Festive Season Boom.
Brexpiprazole tablets are indicated for use as an adjunctive therapy to anti-depressants for the treatment of major depressive disorder (MDD) and for treatment of schizophrenia.
As per IQVIA MAT July 2021 data, Brexpiprazole tablets had estimated annual sales of USD 1,258 million in the US, it added.
Shares of Lupin Ltd closed at Rs 947.65 per scrip on the BSE, down 1.65 per cent from their previous close.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)